The Fort Myers, Fla., oncology testing services company on Friday said Tony Zook, an independent board member since 2023, will succeed Smith as CEO on that date. NeoGenomics said Smith ...

NeoGenomics Inc. shared a strong financial outlook for 2025 and beyond. The Fort Myers-based cancer testing and research lab ...

At that time, Tony Zook, an independent board member, will assume the role of CEO. He's been on the board since 2023. Shares fell by more than 17% on the news of a leadership change. To ensure ...

NeoGenomics shares dropped 19.4% after announcing CEO Chris Smith’s retirement, with Tony Zook. While Zook brings significant healthcare leadership experience, investors are cautious about the ...

Instead, Tony Zook, an independent board member since 2023, will succeed Smith as CEO, also effective April 1. He most recently served as a partner with specialized healthcare consultancy Lucius ...

Tony Zook, an independent board member since 2023, will assume the role of CEO at that time. “Chris has provided exceptional leadership for NeoGenomics, joining the Company at a critical time ...

Tony Zook, an experienced healthcare executive, will succeed Smith as CEO, bringing expertise in commercial operations and strategic leadership. Under Smith’s leadership, NeoGenomics transformed ...

Tony Zook, an independent board member since 2023, will assume the role of CEO at that time. Smith will remain with the company as an advisor throughout the transition. Zook is a partner with ...

NeoGenomics has announced a new CEO. The Fort Myers-based cancer testing and research lab, with a national footprint, shared the news Friday, via a press release. Chris Smith, the public company's ...